Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
ELISA Kit for Growth Arrest Specific Protein 6 (GAS6)
AXLLG; AXSF; AXL Stimulatory Factor; AXL receptor tyrosine kinase ligand
- Product No.SEA204Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range31.2-2,000pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 12.9pg/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 441
For more details, please contact local distributors! US$ 630 US$ 2835 US$ 5355 US$ 44100
Specificity
This assay has high sensitivity and excellent specificity for detection of Growth Arrest Specific Protein 6 (GAS6).
No significant cross-reactivity or interference between Growth Arrest Specific Protein 6 (GAS6) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Growth Arrest Specific Protein 6 (GAS6) and the recovery rates were calculated by comparing the measured value to the expected amount of Growth Arrest Specific Protein 6 (GAS6) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 91-98 | 94 |
EDTA plasma(n=5) | 90-104 | 94 |
heparin plasma(n=5) | 96-105 | 101 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Growth Arrest Specific Protein 6 (GAS6) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Growth Arrest Specific Protein 6 (GAS6) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Growth Arrest Specific Protein 6 (GAS6) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 83-103% | 92-105% | 93-101% | 97-104% |
EDTA plasma(n=5) | 83-92% | 82-96% | 95-102% | 78-102% |
heparin plasma(n=5) | 82-103% | 84-99% | 88-101% | 98-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
- Single-component Reagents of Assay Kit
- Lysis Buffer Specific for ELISA / CLIA
- Quality Control of Kit
- ELISA Kit Customized Service
- Disease Model Customized Service
- Serums Customized Service
- TGFB1 Activation Reagent
- Real Time PCR Experimental Service
- Streptavidin
- Fast blue Protein Stain solution
- Single-component Reagents of FLIA Kit
- Streptavidin-Agarose Beads
Magazine | Citations |
Acta Pharmacol Sin. | Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells. pubmed:27890915 |
Frontiers of Medicine | The effects of Parenteral K1 administration in Pseudoxanthoma elasticum Patients Versus controls. a Pilot study Pubmed:29713628 |
Oncotarget | DAPK and CIP2A are involved in GAS6/AXL-mediated Schwann cell proliferation in a rat model of bilateral cavernous nerve injury Pubmed:29464081 |
journal of nutritional biochemistry | Gamma-glutamyl carboxylated Gas6 mediates the beneficial effect of vitamin K on lowering hyperlipidemia via regulating the AMPK/SREBP1/PPARα signaling … Pubmed: 31226525 |
CELL DEATH AND DIFFERENTIATION | KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway Pubmed: 33139930 |
重度子痫前期患者血清GAS6 与其他炎症因子的相关性研究 | |
JOURNAL OF NUTRITIONAL BIOCHEMISTRY | Gamma-glutamyl carboxylated Gas6 facilitates the prophylactic effect of vitamin K in inhibiting hyperlipidemia-associated inflammatory pathophysiology via arresting MCP-1/ICAM-1 mediated monocyte-hepatocyte adhesion 33789149 |